Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

636 ARTÍCULOS , VIENDO DEL 301 AL 315

Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice

Mestre TA, Shamy M, Benedetti F, Lang AE.

Mov Disord. 2018 Aug;33(8):1195-1203. doi: 10.1002/mds.27409. Epub 2018 Aug 25.

Parkinson Disease

Homayoun H.

Ann Intern Med. 2018 Sep 4;169(5):ITC33-ITC48. doi: 10.7326/AITC201809040.

Chaperone-mediated autophagy as a therapeutic target for Parkinson disease

Campbell P, Morris H, Schapira A.

Expert Opin Ther Targets. 2018 Oct;22(10):823-832. doi: 10.1080/14728222.2018.1517156. Epub 2018 Sep 10.

Comparison of tractography-assisted to atlas-based targeting for deep brain stimulation in essential tremor

Fenoy AJ, Schiess MC.

Mov Disord. 2018 Dec;33(12):1895-1901. doi: 10.1002/mds.27463. Epub 2018 Sep 5.

Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study

Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE.

Mov Disord. 2018 Aug;33(8):1272-1280. doi: 10.1002/mds.27457. Epub 2018 Sep 7.

Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations

Pchelina S, Baydakova G, Nikolaev M, Senkevich K, Emelyanov A, Kopytova A, Miliukhina I, Yakimovskii A, Timofeeva A, Berkovich O, Fedotova E, Illarioshkin S, Zakharova E.

Mov Disord. 2018 Aug;33(8):1325-1330. doi: 10.1002/mds.27393. Epub 2018 Sep 7.

MicroRNAs to differentiate Parkinsonian disorders: Advances in biomarkers and therapeutics

Ramaswamy P, Christopher R, Pal PK, Yadav R.

J Neurol Sci. 2018 Nov 15;394:26-37. doi: 10.1016/j.jns.2018.08.032. Epub 2018 Aug 31.

Holmes' or functional tremor?

Bocci T, Ardolino G, Parenti L, Barloscio D, De Rosa A, Priori A, Sartucci F.

Clin Neurophysiol Pract. 2018 Apr 21;3:104-106. doi: 10.1016/j.cnp.2018.03.006. eCollection 2018.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.

The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders

Damato V, Balint B, Kienzler AK, Irani SR.

Mov Disord. 2018 Sep;33(9):1376-1389. doi: 10.1002/mds.27446. Epub 2018 Sep 14.

Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review

van der Velden RMJ, Broen MPG, Kuijf ML, Leentjens AFG.

Mov Disord. 2018 Oct;33(10):1521-1527. doi: 10.1002/mds.27465. Epub 2018 Sep 17.

Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going

Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ.

Mov Disord. 2018 Aug;33(8):1213-1227. doi: 10.1002/mds.27438.

What Is the Best Electrophysiologic Marker of the Outcome of Subthalamic Nucleus Stimulation in Parkinson Disease?

Boëx C, Tyrand R, Horvath J, Fleury V, Sadri S, Corniola M, Burkhard PR, Momjian S.

World Neurosurg. 2018 Dec;120:e1217-e1224. doi: 10.1016/j.wneu.2018.09.047. Epub 2018 Sep 18.

Parkinson's disease: Cause factors, measurable indicators, and early diagnosis

Bhat S, Acharya UR, Hagiwara Y, Dadmehr N, Adeli H.

Comput Biol Med. 2018 Nov 1;102:234-241. doi: 10.1016/j.compbiomed.2018.09.008. Epub 2018 Sep 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias